Literature DB >> 34225657

Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above.

Mohamed Ahmed Syed1, Ahmed Sameer Al Nuaimi2, Hamda Abdulla A/Qotba2, Gheyath K Nasrallah3,4, Asmaa A Althani3,4, Hadi M Yassine3,4, Abduljaleel Abdullatif Zainel2, Hanan Khudadad2, Tamara Marji2, Shajitha Thekke Veettil2, Hadeel T Al-Jighefee3,4, Salma Younes3,4, Farah Shurrab3,4, Duaa W Al-Sadeq3,4, Al Anoud Saleh AlFehaidi2, Ameena Ibrahim Yfakhroo2, Meshal Abdulla AlMesaifri2, Hanan Al Mujalli5, Samya Ahmad Al Abdulla6, Mohamed Ghaith Al Kuwari7, Faruk Mohammed Azad8, Badria Ali Mohamed Al Malki2, Mariam Ali Abdulmalik2.   

Abstract

BACKGROUND: There is an urgent need to elucidate the epidemiology of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and characterize its potential impact. Investing in characterising the SARS-CoV2 will help plan and improve the response to the pandemic. Furthermore, it will help identify the most efficient ways of managing the pandemic, avoiding public health policies and interventions that may be unduly restrictive of normal activity or unnecessarily costly. This paper describes the design and reports findings of a population based epidemiological study undertaken to characterise SARS-CoV2 in Qatar using limited resources in a timely manner.
METHODS: Asymptomatic individuals ≥10 years registered with Qatar's publicly funded primary health provider were eligible. A stratified random sampling technique was utilized to identify the study sample. Participants were invited to an appointment where they completed a questionnaire and provided samples for polymerase chain reaction and Immunoglobulin M and G immunoassay tests. Data collected were analyzed to calculate point and period prevalence by sociodemographic, lifestyle and clinical characteristics.
RESULTS: Of 18,918 individuals invited for the study, 2084 participated (response rate 10.8%). The overall point prevalence and period prevalence were estimated to be 1.6% (95% CI 1.1-2.2) and 14.6% (95% CI 13.1-16.2) respectively. Period prevalence of SARS-CoV2 infection was not considerably different across age groups (9.7-19.8%). It was higher in males compared to females (16.2 and 12.7% respectively). A significant variation was observed by nationality (7.1 to 22.2%) and municipalities (6.9-35.3%).
CONCLUSIONS: The study provides an example of a methodologically robust approach that can be undertaken in a timely manner with limited resources. It reports much-needed epidemiological data about the spread of SARS-CoV2. Given the low prevalence rates, majority of the population in Qatar remains susceptible. Enhanced surveillance must continue to be in place, particularly due to the large number of asymptomatic cases observed. Robust contact tracing and social distancing measures are key to prevent future outbreaks.

Entities:  

Keywords:  COVID-19; Epidemiology; Primary care; SARS-CoV2

Year:  2021        PMID: 34225657     DOI: 10.1186/s12879-021-06251-z

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  7 in total

1.  Defining the Epidemiology of Covid-19 - Studies Needed.

Authors:  Marc Lipsitch; David L Swerdlow; Lyn Finelli
Journal:  N Engl J Med       Date:  2020-02-19       Impact factor: 91.245

2.  The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review.

Authors:  Duaa W Al-Sadeq; Gheyath K Nasrallah
Journal:  Int J Infect Dis       Date:  2020-07-02       Impact factor: 3.623

3.  The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries.

Authors:  Michael C Grant; Luke Geoghegan; Marc Arbyn; Zakaria Mohammed; Luke McGuinness; Emily L Clarke; Ryckie G Wade
Journal:  PLoS One       Date:  2020-06-23       Impact factor: 3.240

4.  SARS-CoV-2 infection serology: a useful tool to overcome lockdown?

Authors:  Marzia Nuccetelli; Massimo Pieri; Sandro Grelli; Marco Ciotti; Roberto Miano; Massimo Andreoni; Sergio Bernardini
Journal:  Cell Death Discov       Date:  2020-05-26

5.  Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?

Authors:  Konstantinos Farsalinos; Anastasia Barbouni; Raymond Niaura
Journal:  Intern Emerg Med       Date:  2020-05-09       Impact factor: 3.397

Review 6.  The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence mechanism and therapeutic modalities.

Authors:  Shatha K Alyammahi; Shifaa M Abdin; Dima W Alhamad; Sara M Elgendy; Amani T Altell; Hany A Omar
Journal:  Infect Genet Evol       Date:  2020-11-29       Impact factor: 3.342

7.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

  7 in total
  3 in total

Review 1.  Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination.

Authors:  Rupinder Kaur; Shareen Singh; Thakur Gurjeet Singh; Pragati Sood; Jiki Robert
Journal:  Inflammopharmacology       Date:  2022-01-03       Impact factor: 5.093

2.  Breast Cancer Knowledge, Attitudes and Practices amongst Women in Qatar.

Authors:  Ehab Hamed; Bayan Alemrayat; Mohamed Ahmed Syed; Suhad Daher-Nashif; Hadi Mohamad Abu Rasheed; Tanya Kane
Journal:  Int J Environ Res Public Health       Date:  2022-03-28       Impact factor: 3.390

3.  Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.

Authors:  Farah M Shurrab; Nadin Younes; Duaa W Al-Sadeq; Na Liu; Hamda Qotba; Laith J Abu-Raddad; Gheyath K Nasrallah
Journal:  Int J Infect Dis       Date:  2022-02-26       Impact factor: 12.074

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.